Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enbrel via Sofusa DoseConnect in Rheumatoid Arthritis
NCT04559412Phase 1Unknown
- Sponsor
- Sorrento Therapeutics
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of etanercept in rheumatoid arthritis (RA), sponsored by Sorrento Therapeutics. Primary endpoint: Incidence and severity of adverse events and their relationships to SOFUSA administration at Week 12. Status: unknown.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04559412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04559412.